{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:35:00Z","timestamp":1792802100333,"version":"4.5.0"},"reference-count":79,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kyowa Kirin International plc","id":[{"id":"https:\/\/ror.org\/017hh7b56","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>X-linked hypophosphatemia (XLH) is a rare, hereditary, progressive musculoskeletal disease that often causes pain and short stature, as well as decreased physical function, mobility, and quality of life. Hypophosphatemia in XLH is caused by loss of function mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene, resulting in excess levels of the phosphate-regulating hormone fibroblast growth factor 23 (FGF23), which leads to renal phosphate wasting and decreased serum 1,25-dihydroxyvitamin D production. Historically, treatment options were limited to oral phosphate and active vitamin D analogues (conventional management) dosed several times daily in an attempt to improve skeletal mineralization by increasing serum phosphorus. The recent approval of burosumab, a fully human monoclonal antibody to FGF23, has provided a new, targeted treatment option for patients with XLH. This review summarizes our current understanding of XLH, the safety and efficacy of conventional management and burosumab, existing recommendations for managing patients, and unanswered questions in the field.<\/jats:p>","DOI":"10.1210\/jendso\/bvaa151","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T14:14:04Z","timestamp":1602684844000},"source":"Crossref","is-referenced-by-count":59,"title":["X-Linked Hypophosphatemia: A New Era in Management"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-9138","authenticated-orcid":false,"given":"Kathryn","family":"Dahir","sequence":"first","affiliation":[{"name":"Endocrinology and Diabetes, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Scott","family":"Roberts","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc, Novato, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Krolczyk","sequence":"additional","affiliation":[{"name":"Ultragenyx Pharmaceutical Inc, Novato, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill H","family":"Simmons","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"issue":"3","key":"2021042006034801700_CIT0001","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Beck-Nielsen","year":"2009","journal-title":"Eur J Endocrinol."},{"issue":"7","key":"2021042006034801700_CIT0002","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2021042006034801700_CIT0003","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol."},{"key":"2021042006034801700_CIT0004","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-1-4614-0887-1_4","article-title":"Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis","volume":"728","author":"Martin","year":"2012","journal-title":"Adv Exp Med Biol."},{"issue":"8","key":"2021042006034801700_CIT0005","doi-asserted-by":"crossref","first-page":"e10190","DOI":"10.1002\/jbm4.10190","article-title":"FGF23, hypophosphatemia, and emerging treatments","volume":"3","author":"Imel","year":"2019","journal-title":"JBMR Plus."},{"issue":"2","key":"2021042006034801700_CIT0006","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00247-012-2532-x","article-title":"Rickets: part I","volume":"43","author":"Shore","year":"2013","journal-title":"Pediatr Radiol."},{"issue":"21","key":"2021042006034801700_CIT0007","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"2021042006034801700_CIT0008","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00431-007-0662-1","article-title":"What\u2019s new in hypophosphataemic rickets?","volume":"167","author":"Pettifor","year":"2008","journal-title":"Eur J Pediatr."},{"key":"2021042006034801700_CIT0009","first-page":"1","article-title":"X-linked hypophosphatemia.","volume-title":"GeneReviews","author":"Ruppe","year":"1993"},{"issue":"8","key":"2021042006034801700_CIT0010","doi-asserted-by":"crossref","first-page":"E1492","DOI":"10.1210\/jc.2012-1336","article-title":"Abnormalities in muscle density and muscle function in hypophosphatemic rickets","volume":"97","author":"Veilleux","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021042006034801700_CIT0011","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","article-title":"Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations","volume":"41","author":"Chesher","year":"2018","journal-title":"J Inherit Metab Dis."},{"issue":"2","key":"2021042006034801700_CIT0012","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1148\/radiology.171.2.2539609","article-title":"X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features","volume":"171","author":"Hardy","year":"1989","journal-title":"Radiology."},{"issue":"8","key":"2021042006034801700_CIT0013","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2021042006034801700_CIT0014","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00005792-198911000-00002","article-title":"X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults","volume":"68","author":"Reid","year":"1989","journal-title":"Medicine (Baltimore)."},{"issue":"9","key":"2021042006034801700_CIT0015","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J."},{"issue":"2","key":"2021042006034801700_CIT0016","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0002-9343(64)90085-3","article-title":"Vitamin D-resistant rickets: analysis of twenty-four pedigrees with hereditary and sporadic cases","volume":"36","author":"Burnett","year":"1964","journal-title":"Am J Med."},{"issue":"2","key":"2021042006034801700_CIT0017","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021042006034801700_CIT0018","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00223-010-9373-0","article-title":"Phenotype presentation of hypophosphatemic rickets in adults","volume":"87","author":"Beck-Nielsen","year":"2010","journal-title":"Calcif Tissue Int."},{"issue":"1","key":"2021042006034801700_CIT0019","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/jbmr.2307","article-title":"PHEX 3\u2032-UTR c.*231A\u2005&gt;\u2005G near the polyadenylation signal is a relatively common, mild, American mutation that masquerades as sporadic or X-linked recessive hypophosphatemic rickets","volume":"30","author":"Mumm","year":"2015","journal-title":"J Bone Miner Res."},{"key":"2021042006034801700_CIT0020","article-title":"Primary disorders of phosphate metabolism.","volume-title":"Endotext","author":"Carpenter","year":"2000"},{"issue":"6","key":"2021042006034801700_CIT0021","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1159\/000495393","article-title":"Phosphate homeostasis, inflammation and the regulation of FGF-23","volume":"43","author":"Lang","year":"2018","journal-title":"Kidney Blood Press Res."},{"issue":"5","key":"2021042006034801700_CIT0022","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J Clin Invest."},{"issue":"2","key":"2021042006034801700_CIT0023","doi-asserted-by":"crossref","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","article-title":"FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1","volume":"297","author":"Gattineni","year":"2009","journal-title":"Am J Physiol Renal Physiol."},{"issue":"3","key":"2021042006034801700_CIT0024","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.ki.5000168","article-title":"Fibroblast growth factor 23: the making of a hormone","volume":"69","author":"Schiavi","year":"2006","journal-title":"Kidney Int."},{"issue":"5","key":"2021042006034801700_CIT0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00774-015-0698-7","article-title":"Pathogenesis and diagnostic criteria for rickets and osteomalacia\u2014proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society","volume":"33","author":"Fukumoto","year":"2015","journal-title":"J Bone Miner Metab."},{"issue":"2","key":"2021042006034801700_CIT0026","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jbmr.544","article-title":"A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells","volume":"27","author":"Ichikawa","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"11","key":"2021042006034801700_CIT0027","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00467-012-2175-z","article-title":"Phosphate homeostasis and its role in bone health","volume":"27","author":"Goretti Penido","year":"2012","journal-title":"Pediatr Nephrol."},{"issue":"1","key":"2021042006034801700_CIT0028","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect."},{"issue":"4","key":"2021042006034801700_CIT0029","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00774-009-0079-1","article-title":"Hypophosphatemia: the common denominator of all rickets","volume":"27","author":"Tiosano","year":"2009","journal-title":"J Bone Miner Metab."},{"issue":"11","key":"2021042006034801700_CIT0030","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s00198-018-4618-2","article-title":"Phosphate wasting disorders in adults","volume":"29","author":"Marcucci","year":"2018","journal-title":"Osteoporos Int."},{"issue":"2","key":"2021042006034801700_CIT0031","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bone.2013.01.046","article-title":"Osteocyte regulation of phosphate homeostasis and bone mineralization underlies the pathophysiology of the heritable disorders of rickets and osteomalacia","volume":"54","author":"Feng","year":"2013","journal-title":"Bone."},{"issue":"7","key":"2021042006034801700_CIT0032","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol."},{"issue":"11","key":"2021042006034801700_CIT0033","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.2215\/CJN.03000509","article-title":"The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport","volume":"4","author":"Levine","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"2021042006034801700_CIT0034","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00467-012-2364-9","article-title":"Hypophosphatemia and growth","volume":"28","author":"Santos","year":"2013","journal-title":"Pediatr Nephrol."},{"issue":"5","key":"2021042006034801700_CIT0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/adc.57.5.359","article-title":"Bone mineral homeostasis, bone growth, and mineralisation during years of pubertal growth: a unifying concept","volume":"57","author":"Krabbe","year":"1982","journal-title":"Arch Dis Child."},{"issue":"2","key":"2021042006034801700_CIT0036","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0031-3955(05)70485-5","article-title":"New perspectives on the biology and treatment of X-linked hypophosphatemic rickets","volume":"44","author":"Carpenter","year":"1997","journal-title":"Pediatr Clin North Am."},{"issue":"7","key":"2021042006034801700_CIT0037","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/jhg.2012.56","article-title":"Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets","volume":"57","author":"Beck-Nielsen","year":"2012","journal-title":"J Hum Genet."},{"issue":"4","key":"2021042006034801700_CIT0038","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00439-009-0631-z","article-title":"PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets","volume":"125","author":"Gaucher","year":"2009","journal-title":"Hum Genet."},{"issue":"11","key":"2021042006034801700_CIT0039","first-page":"4075","article-title":"X-linked hypophosphatemia: a search for gender, race, anticipation, or parent of origin effects on disease expression in children","volume":"81","author":"Whyte","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021042006034801700_CIT0040","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.amjmed.2005.02.014","article-title":"Hypophosphatemia: an update on its etiology and treatment","volume":"118","author":"Gaasbeek","year":"2005","journal-title":"Am J Med."},{"issue":"5","key":"2021042006034801700_CIT0041","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10067-014-2627-x","article-title":"Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients","volume":"35","author":"Mateo","year":"2016","journal-title":"Clin Rheumatol."},{"issue":"4","key":"2021042006034801700_CIT0042","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone."},{"issue":"3","key":"2021042006034801700_CIT0043","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1067\/mpd.2003.119","article-title":"Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D","volume":"142","author":"Chaussain-Miller","year":"2003","journal-title":"J Pediatr."},{"issue":"8","key":"2021042006034801700_CIT0044","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021042006034801700_CIT0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(81)80951-1","article-title":"Long-term treatment of familial hypophosphatemic rickets with oral phosphate and 1\u03b1-hydroxyvitamin D3","volume":"99","author":"Rasmussen","year":"1981","journal-title":"J Pediatr."},{"issue":"2","key":"2021042006034801700_CIT0046","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00193821","article-title":"X-linked hypophosphatemic rickets without \u201crickets\u201d","volume":"20","author":"Econs","year":"1991","journal-title":"Skeletal Radiol."},{"issue":"1","key":"2021042006034801700_CIT0047","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0169-6009(08)80127-4","article-title":"X-linked hypophosphatemic rickets: a disease often unknown to affected patients","volume":"24","author":"Econs","year":"1994","journal-title":"Bone Miner."},{"issue":"2","key":"2021042006034801700_CIT0048","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5395\/rde.2017.42.2.146","article-title":"Dental management of patients with X-linked hypophosphatemia","volume":"42","author":"LE","year":"2017","journal-title":"Restor Dent Endod."},{"issue":"7","key":"2021042006034801700_CIT0049","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc."},{"issue":"3","key":"2021042006034801700_CIT0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"2021042006034801700_CIT0051","first-page":"A4874","article-title":"Treatment of hypophosphataemic rickets in children remains a challenge","volume":"61","author":"Nielsen","year":"2014","journal-title":"Dan Med J."},{"key":"2021042006034801700_CIT0052","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1177\/0022034514529150","article-title":"Rare bone diseases and their dental, oral, and craniofacial manifestations","volume":"93","author":"Foster","year":"2014","journal-title":"J Dent Res."},{"issue":"6","key":"2021042006034801700_CIT0053","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","article-title":"X-linked hypophosphatemia: management and treatment prospects","volume":"86","author":"Lambert","year":"2019","journal-title":"Joint Bone Spine."},{"issue":"10","key":"2021042006034801700_CIT0054","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1590\/S1807-59322010001000017","article-title":"Dental abnormalities and oral health in patients with hypophosphatemic rickets","volume":"65","author":"Souza","year":"2010","journal-title":"Clinics (S\u00e3o Paulo, Brazil)."},{"issue":"2","key":"2021042006034801700_CIT0055","first-page":"91","article-title":"Prevalence of dental abscess in a population of children with vitamin D-resistant rickets","volume":"13","author":"McWhorter","year":"1991","journal-title":"Pediatr Dent."},{"issue":"3","key":"2021042006034801700_CIT0056","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/jbmr.3614","article-title":"High incidence of cranial synostosis and Chiari I malformation in children with X-linked hypophosphatemic rickets (XLHR)","volume":"34","author":"Rothenbuhler","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2021042006034801700_CIT0057","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"2021042006034801700_CIT0058","doi-asserted-by":"crossref","first-page":"230","DOI":"10.7326\/0003-4819-100-2-230","article-title":"Impaired hearing in X-linked hypophosphataemic (vitamin-D-resistant) osteomalacia","volume":"100","author":"Davies","year":"1984","journal-title":"Ann Intern Med."},{"issue":"5","key":"2021042006034801700_CIT0059","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0009-9260(88)80224-1","article-title":"The petrous temporal bone and deafness in X-linked hypophosphataemic osteomalacia","volume":"39","author":"O\u2019Malley","year":"1988","journal-title":"Clin Radiol."},{"issue":"2","key":"2021042006034801700_CIT0060","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00247-012-2536-6","article-title":"Rickets: part II","volume":"43","author":"Shore","year":"2013","journal-title":"Pediatr Radiol."},{"issue":"3","key":"2021042006034801700_CIT0061","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00223-009-9270-6","article-title":"Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice","volume":"85","author":"Liang","year":"2009","journal-title":"Calcif Tissue Int."},{"issue":"5","key":"2021042006034801700_CIT0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.2783","article-title":"1,25-Dihydroxyvitamin D alone improves skeletal growth, microarchitecture, and strength in a murine model of XLH, despite enhanced FGF23 expression","volume":"31","author":"Liu","year":"2016","journal-title":"J Bone Miner Res."},{"issue":"15","key":"2021042006034801700_CIT0063","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1242\/dev.163519","article-title":"Molecular analysis of enthesopathy in a mouse model of hypophosphatemic rickets","volume":"145","author":"Liu","year":"2018","journal-title":"Development."},{"issue":"3","key":"2021042006034801700_CIT0064","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.4158\/EP15858.CR","article-title":"Hereditary X-linked hypophosphatemia and thoracic myelopathy","volume":"2","author":"Forrest","year":"2016","journal-title":"AACE Clin Case Rep."},{"issue":"1","key":"2021042006034801700_CIT0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198507043130101","article-title":"Calcification of entheses associated with X-linked hypophosphatemic osteomalacia","volume":"313","author":"Polisson","year":"1985","journal-title":"N Engl J Med."},{"issue":"10","key":"2021042006034801700_CIT0066","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1096\/fj.201600473R","article-title":"Hypophosphatemia promotes lower rates of muscle ATP synthesis","volume":"30","author":"Pesta","year":"2016","journal-title":"FASEB J."},{"issue":"1","key":"2021042006034801700_CIT0067","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13023-016-0538-4","article-title":"Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia","volume":"11","author":"Forestier-Zhang","year":"2016","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"2021042006034801700_CIT0068","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s12325-019-01193-0","article-title":"Exploring the burden of X-linked hypophosphataemia: an opportunistic qualitative study of patient statements generated during a technology appraisal","volume":"37","author":"Ferizovi\u0107","year":"2020","journal-title":"Adv Ther."},{"key":"2021042006034801700_CIT0069","author":"National Organization for Rare Disorders","year":"2019"},{"issue":"4 Suppl 1","key":"2021042006034801700_CIT0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0026-0495(90)90264-D","article-title":"Calcitriol treatment in vitamin D-dependent and vitamin D-resistant rickets","volume":"39","author":"Glorieux","year":"1990","journal-title":"Metabolism."},{"issue":"4","key":"2021042006034801700_CIT0071","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.2009-1671","article-title":"Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations","volume":"95","author":"Imel","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"10189","key":"2021042006034801700_CIT0072","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet."},{"issue":"10","key":"2021042006034801700_CIT0073","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1210\/JC.2015-2199","article-title":"Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease","volume":"100","author":"Connor","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021042006034801700_CIT0074","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2012.07.037","article-title":"Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement","volume":"57","author":"Schaefer","year":"2012","journal-title":"J Hepatol."},{"key":"2021042006034801700_CIT0075","article-title":"CRYSVITA (burosumab","year":"2019"},{"key":"2021042006034801700_CIT0076","author":"Ultragenyx Pharmaceutical Inc.","year":"2019"},{"key":"2021042006034801700_CIT0077","author":"European Medicines Agency","year":"2018"},{"issue":"12","key":"2021042006034801700_CIT0078","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial","volume":"34","author":"Insogna","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2021042006034801700_CIT0079","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"Portale","year":"2019","journal-title":"Calcif Tissue Int."}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaa151\/33883790\/bvaa151.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/4\/12\/bvaa151\/37182038\/bvaa151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/4\/12\/bvaa151\/37182038\/bvaa151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T03:51:59Z","timestamp":1618890719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaa151\/5923329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaa151","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,10,14]]},"article-number":"bvaa151"}}